Almirall has taken another step forwards in the development of a digital approach to managing and treating dermatological conditions, forming a three-year alliance with Mi
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in
A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea
Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and
With the northern hemisphere summer drawing near, a campaign has been launched to raise awareness of actinic keratosis – a skin condition caused by sun exposure that can l
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.